Your browser doesn't support javascript.
Single-Cell Gene Expression Analysis Revealed Immune Cell Signatures of Delta COVID-19.
Shaymardanov, Abusaid M; Antonova, Olga A; Sokol, Anastasia D; Deinichenko, Kseniia A; Kazakova, Polina G; Milovanov, Mikhail M; Zakubansky, Alexander V; Akinshina, Alexandra I; Tsypkina, Anastasia V; Romanova, Svetlana V; Muhin, Vladimir E; Mitrofanov, Sergey I; Yudin, Vladimir S; Yudin, Sergey M; Makhotenko, Antonida V; Keskinov, Anton A; Kraevoy, Sergey A; Snigir, Ekaterina A; Svetlichnyy, Dmitry V; Skvortsova, Veronika I.
  • Shaymardanov AM; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Antonova OA; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Sokol AD; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Deinichenko KA; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Kazakova PG; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Milovanov MM; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Zakubansky AV; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Akinshina AI; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Tsypkina AV; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Romanova SV; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Muhin VE; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Mitrofanov SI; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Yudin VS; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Yudin SM; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Makhotenko AV; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Keskinov AA; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Kraevoy SA; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Snigir EA; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Svetlichnyy DV; Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  • Skvortsova VI; The Federal Medical Biological Agency (FMBA of Russia), 30 Volokolamskoe sh., Moscow 125310, Russia.
Cells ; 11(19)2022 09 21.
Article in English | MEDLINE | ID: covidwho-2043596
ABSTRACT
The coronavirus disease 2019 (COVID-19) is accompanied by a cytokine storm with the release of many proinflammatory factors and development of respiratory syndrome. Several SARS-CoV-2 lineages have been identified, and the Delta variant (B.1.617), linked with high mortality risk, has become dominant in many countries. Understanding the immune responses associated with COVID-19 lineages may therefore aid the development of therapeutic and diagnostic strategies. Multiple single-cell gene expression studies revealed innate and adaptive immunological factors and pathways correlated with COVID-19 severity. Additional investigations covering host-pathogen response characteristics for infection caused by different lineages are required. Here, we performed single-cell transcriptome profiling of blood mononuclear cells from the individuals with different severity of the COVID-19 and virus lineages to uncover variant specific molecular factors associated with immunity. We identified significant changes in lymphoid and myeloid cells. Our study highlights that an abundant population of monocytes with specific gene expression signatures accompanies Delta lineage of SARS-CoV-2 and contributes to COVID-19 pathogenesis inferring immune components for targeted therapy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Topics: Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: Cells11192950

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Topics: Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: Cells11192950